[{"indications": "Indications\u00a0\n(From Interferon beta: British National Formulary)\nInterferon beta and under preparations", "name": "INTERFERON BETA Interferon beta-1a", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.4 Other immunomodulating drugs", "Interferon beta", "INTERFERON BETA", "Interferon beta-1a"], "cautions": "Cautions\u00a0\n(From Interferon beta: British National Formulary)\nCautions\u00a0Caution is advised in those with severe hepatic or renal impairment or a history of cardiac disorders, depressive disorders (avoid in severe depression or in those with suicidal ideation), seizures, or severe myelosupression. Patients should be monitored for signs of hepatic injury.  and consult product literature", "side-effects": "Side-effects\u00a0\n(From Interferon beta: British National Formulary)\nInterferon beta and consult product literature", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/70429.htm", "doses": ["See under preparations", "Name[Rebif\u00ae (Merck Serono) ] Injection, interferon beta-1a, net price 22-microgram (6\u00a0million-unit) prefilled syringe =\r\n\u00a352.07; 44-microgram (12\u00a0million-unit) prefilled syringe = \u00a367.77;\r\nstarter pack of 6 \u00d7 8.8-microgram (2.4\u00a0million-unit) prefilled syringes\r\nwith 6 \u00d7 22-microgram (6\u00a0million-unit) prefilled syringes = \u00a3552.19Note\u00a0For subcutaneous injection\nExcipients  include benzyl alcohol (avoid in neonates, see Excipients)\nInjection, interferon beta-1a, 44\u00a0micrograms (12 million-units/mL), net price 1.5\u00a0mL (66-microgram,\r\n18\u00a0million-unit) cartridge = \u00a3203.31; 88-micrograms (24\u00a0million-units/mL),\r\n1.5\u00a0mL (132-microgram, 36 million-unit) cartridge = \u00a3171.97; starter\r\npack of 2 \u00d7 1.5\u00a0mL (132-microgram, 36 million-unit) cartridge = \u00a3406.61Note\u00a0Cartridges for use with RebiSmart\u00ae auto-injector\r\ndevice. For subcutaneous injection\nExcipients  include benzyl alcohol (avoid in neonates, see Excipients)\nInjection (RebiDose\u00ae), interferon\r\nbeta-1a, net price 22-microgram (6 million-unit) prefilled pen = \u00a352.06;\r\n44-microgram (12 million-unit) prefilled pen = \u00a367.77; starter pack\r\nof 6 \u00d7 8.8-microgram (2.4 million-unit) prefilled pens with 6 \u00d7 22-microgram\r\n(6 million-unit) prefilled pens = \u00a3552.19Note\u00a0For subcutaneous injection\nExcipients  include benzyl alcohol (avoid in neonates, see Excipients)Dose\u00a0for relapsing, remitting multiple sclerosis, consult product\r\nliterature"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk (toxicity\r\nin animal studies); effective contraception required\r\nduring treatment\u2014consult product literature"}, {"indications": "Indications\u00a0\n(From Interferon beta: British National Formulary)\nInterferon beta and under preparations", "name": "INTERFERON BETA Interferon beta-1b", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.4 Other immunomodulating drugs", "Interferon beta", "INTERFERON BETA", "Interferon beta-1b"], "cautions": "Cautions\u00a0\n(From Interferon beta: British National Formulary)\nCautions\u00a0Caution is advised in those with severe hepatic or renal impairment or a history of cardiac disorders, depressive disorders (avoid in severe depression or in those with suicidal ideation), seizures, or severe myelosupression. Patients should be monitored for signs of hepatic injury.  and consult product literature", "side-effects": "Side-effects\u00a0\n(From Interferon beta: British National Formulary)\nInterferon beta and consult product literature", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202485.htm", "doses": ["See under preparations", "Name[Extavia\u00ae (Novartis) ] Injection, powder for reconstitution,\r\ninterferon beta-1b. Net price 300-microgram (9.6 million-unit) vial\r\nwith diluent = \u00a339.78Note\u00a0for subcutaneous injectionDose\u00a0for relapsing, remitting multiple sclerosis, for secondary\r\nprogressive multiple sclerosis with active disease, or for a single\r\ndemyelinating event with an active inflammatory process (if severe\r\nenough to require intravenous corticosteroid and patient at high risk\r\nof developing multiple sclerosis), consult product literature"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk (toxicity\r\nin animal studies); effective contraception required\r\nduring treatment\u2014consult product literature"}, {"indications": "Indications\u00a0\n(From Interferon beta: British National Formulary)\nInterferon beta and under preparations", "name": "INTERFERON BETA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.4 Other immunomodulating drugs", "Interferon beta"], "cautions": "Cautions\u00a0\n(From Interferon beta: British National Formulary)\nCautions\u00a0Caution is advised in those with severe hepatic or renal impairment or a history of cardiac disorders, depressive disorders (avoid in severe depression or in those with suicidal ideation), seizures, or severe myelosupression. Patients should be monitored for signs of hepatic injury.  and consult product literature", "side-effects": "Side-effects\u00a0\n(From Interferon beta: British National Formulary)\nInterferon beta and consult product literature", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/37090.htm", "doses": ["See under preparations"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk (toxicity\r\nin animal studies); effective contraception required\r\nduring treatment\u2014consult product literature"}]